| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Adams SR et al. | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. | 2016 | Nat Commun | pmid:27698471 |
| Mahtani RL and Vogel CL | When Can a Salvage Therapy (T-DM1) Take the Lead? | 2016 | J. Clin. Oncol. | pmid:27432926 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Chen L et al. | In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. | 2016 | MAbs | pmid:27380163 |
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Dzimitrowicz H et al. | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. | 2016 | J. Clin. Oncol. | pmid:27298406 |
| Wang C et al. | Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. | 2016 | J Chromatogr A | pmid:27286648 |
| Hamblett KJ et al. | Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. | 2016 | Mol. Pharm. | pmid:27248573 |
| Ponte JF et al. | Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. | 2016 | Bioconjug. Chem. | pmid:27174129 |
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Zhang YG et al. | Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. | 2016 | Int. J. Syst. Evol. Microbiol. | pmid:26486850 |
| MartÃnez MT et al. | Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. | 2016 | Crit. Rev. Oncol. Hematol. | pmid:26318092 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Singh AP et al. | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). | 2016 | AAPS J | pmid:27029797 |
| Shen K et al. | Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. | 2016 | Sci Rep | pmid:26979925 |
| Krop IE et al. | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. | 2016 | Breast Cancer Res. | pmid:26979312 |
| de Goeij BE and Lambert JM | New developments for antibody-drug conjugate-based therapeutic approaches. | 2016 | Curr. Opin. Immunol. | pmid:26963132 |
| Maass KF et al. | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. | 2016 | AAPS J | pmid:26912181 |